CAPLIPOINT:NSE-Caplin Point Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 813.40

Change

0.00 (0.00)%

Market Cap

INR 61.80B

Volume

0.06M

Avg Analyst Target

INR 1,000.00 (+22.94%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CAPLIPOINT Stock Forecast & Price:
Based on the Caplin Point Laboratories Limited stock forecasts from 1 analysts, the average analyst target price for Caplin Point Laboratories Limited is INR 1,000.00 over the next 12 months. Caplin Point Laboratories Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Caplin Point Laboratories Limited is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Caplin Point Laboratories Limited’s stock price was INR 813.40. Caplin Point Laboratories Limited’s stock price has changed by -3.51% over the past week, +11.39% over the past month and -11.08% over the last year.

About Caplin Point Laboratories Limited (CAPLIPOINT:NSE)

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositor ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,185.67B 56.23 28.46
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,045.31B 35.31 25.31
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR700.99B 23.63 12.93
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

INR527.28B 65.88 25.93
PEL:NSE Piramal Enterprises Limited

N/A

INR428.64B 22.88 11.63
ALKEM:NSE Alkem Laboratories Limited

N/A

INR356.84B 21.68 21.38
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR332.73B 12.57 7.06
LUPIN:NSE Lupin Limited

N/A

INR302.45B 25.10 -88.82
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR296.62B 35.53 20.32
IPCALAB:NSE IPCA Laboratories Limited

N/A

INR257.55B 29.05 18.32

ETFs Containing CAPLIPOINT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.22% 82% B- 53% F
Dividend Return 0.23% 23% F 12% F
Total Return -4.99% 84% B 53% F
Trailing 12 Months  
Capital Gain -5.36% 75% C 39% F
Dividend Return 0.41% 42% F 23% F
Total Return -4.95% 74% C 38% F
Trailing 5 Years  
Capital Gain 23.65% 39% F 51% F
Dividend Return 1.69% 28% F 23% F
Total Return 25.33% 39% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 15.50% 34% F 48% F
Dividend Return 0.42% 38% F 35% F
Total Return 15.92% 34% F 48% F
Risk Return Profile  
Volatility (Standard Deviation) 43.14% 60% D- 66% D
Risk Adjusted Return 36.90% 45% F 56% F
Market Capitalization 61.80B 71% C- 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.72 62% D- 50% F
Price/Book Ratio 4.19 33% F 27% F
Price / Cash Flow Ratio 18.35 52% F 33% F
EV/EBITDA 12.48 51% F 41% F
Management Effectiveness  
Return on Equity 22.74% 83% B 82% B-
Return on Invested Capital 20.12% 85% B 86% B
Return on Assets 14.02% 90% A- 93% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.43% 20% F 26% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.32 86% B 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.